

Neutralizing Antibody Market Forecasts to 2034 – Global Analysis By Antibody Type (Monoclonal Antibodies, Polyclonal Antibodies, Broadly Neutralizing Antibody, Cross Neutralizing Antibody and Other Antibody Types), Distribution Channel, Application, End User and By Geography

<https://marketpublishers.com/r/NCB4CDDC9BCBEN.html>

Date: April 2026

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: NCB4CDDC9BCBEN

Abstracts

According to Statistics MRC, the Global Neutralizing Antibody Market is accounted for \$257.5 billion in 2026 and is expected to reach \$576.7 billion by 2034 growing at a CAGR of 10.6% during the forecast period. The immune system produces a kind of antibody known as neutralizing antibodies, which are designed to selectively target and inhibit the action of pathogens like bacteria or viruses. These antibodies stop pathogens from infecting or harming host cells by binding to particular areas, frequently on their surface. These antibodies aid the immune system in managing and curing the infection by blocking the pathogen's capacity to enter cells or multiply.

According to the report of GLOBOCAN 2020, there were 19.3 million new cases of cancer and about 10 million deaths due to cancer in the world, and increasing cancer cases are the major growth factor behind the market.

Market Dynamics:

Driver:

Rising numbers of infectious diseases

Infectious disorders including hepatitis, HIV/AIDS, and respiratory infections are still

quite common around the world. A promising therapeutic strategy for the management of these illnesses is the use of neutralizing antibodies. Neutralizing antibodies should become more and more in demand as the incidence of these infectious illnesses rises. Furthermore, it is anticipated that the market would rise in response to the rising prevalence of autoimmune illnesses.

Restraint:

Regulatory challenges

Securing regulatory clearance for novel antibody treatments necessitates thorough assessments of their safety and effectiveness. Comprehensive clinical data is frequently required by regulatory bodies, which might result in lengthier development times and higher costs. Companies may find it difficult to navigate the regulatory environment, particularly when it comes to unique or complicated neutralizing antibodies. The market may be severely constrained by regulatory issues.

Opportunity:

Improvements in antibody engineering and design

Neutralizing antibodies that are optimized can be produced thanks to the ongoing advancements in antibody engineering and design approaches. Affinity maturation and antibody humanization are two techniques used to improve the safety, half-life, and effectiveness of antibodies. Adding new platforms to the mix, including antibody fragments and antibody-drug conjugates, increases the potential for developing therapeutics. This is the main factor driving the market's expansion.

Threat:

Expensive development and treatment costs

The process of creating and producing neutralizing antibodies is expensive and time-consuming. High development costs can be attributed to the considerable research and development activities, clinical trials, and manufacturing expenses. Furthermore, neutralizing antibody therapies might be prohibitively expensive, which may restrict accessibility, especially in healthcare systems with tight budgets and resources.

Covid-19 Impact:

The neutralizing antibody market has been significantly influenced by the COVID-19 pandemic. In order to treat and prevent COVID-19, neutralizing antibodies have been essential. Several monoclonal antibody treatments have been approved or authorized for usage in emergency situations. The market has grown significantly as a result of the spike in demand for neutralizing antibodies against SARS-CoV-2.

The monoclonal antibodies segment is expected to be the largest during the forecast period

The monoclonal antibodies segment is expected to be the largest during the forecast period. The need for goods containing monoclonal antibodies, the expansion of the pharmaceutical and biotechnology sectors, and the availability of enhanced infrastructure for the healthcare industry are all anticipated to fuel the growth of the monoclonal antibody market. The healthcare industry is expanding quickly in emerging countries as a result of the rising need for more advanced sophisticated manufacturing systems and large government investments to modernize healthcare infrastructure.

The research institutes segment is expected to have the highest CAGR during the forecast period

The research institutes segment is expected to have the highest CAGR during the forecast period, owing to the increased incidence of cancer and other chronic illnesses within the anticipated time frame, several organizations have enhanced their research protocols and utilized the funds received to create novel technologies. Funded by public or commercial sources, research institutes conduct investigations on current or forthcoming products that have the potential to be utilized for the diagnosis, treatment, or surveillance of any human ailment.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to the presence of a standard nationwide healthcare system and the existence of significant critical companies. The employment of cutting-edge genetic engineering technology in manufacturing, a sophisticated healthcare system, government support for infection control and management, and a rise in the prevalence of diseases associated with sedentary lifestyles are some of the factors driving the market's growth.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. Factors driving the market expansion include the rise in technical demand for genetic platforms with improved capabilities, the expansion of research and development activities in the field of genomics, and the growing awareness among patients about the potential benefits of monoclonal antibodies (mAb) therapy. The market's growth is also fueled by the expansion of the R&D industry and technical advancements in the manufacturing of monoclonal antibodies.

Key players in the market

Some of the key players in Neutralizing Antibody market include GlaxoSmithKline plc, Novartis AG, Regeneron Pharmaceuticals, Inc., Roche Holding AG, Eli Lilly and Company, Sanofi SA, AstraZeneca PLC, Merck & Co.Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Moderna, Inc., Johnson & Johnson, BioNTech SE, CSL Limite, Sinovac Biotech Ltd and HaemaLogiX Ltd.

Key Developments:

In February 2022, Eli Lilly and Company announced that United States Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant.

In January 2022, HaemaLogiX Ltd (HaemaLogiX) and Lonza entered into an agreement to manufacture the next clinical batch (cGMP) of HaemaLogiX's lead multiple myeloma drug candidate, KappaMab, a monoclonal antibody that binds to a cell surface target called kappa myeloma antigen (KMA) that is only found on myeloma cancer cells and not on normal plasma cells.

Antibody Types Covered:

Monoclonal Antibodies

Polyclonal Antibodies

Broadly Neutralizing Antibody

Cross Neutralizing Antibody

Other Antibody Types

Target Viruses Covered:

SARS-CoV-2

Influenza

HIV

Ebola

Hepatitis C

Zika

Other Target Viruses

Distribution Channels Covered:

Distributors

Online Retail

Applications Covered:

Diagnostics

Therapeutics

Research & Development

Other Applications

End Users Covered:

Hospitals

Pharmaceutical Companies

Laboratories

Other End Users

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments

Strategic recommendations for the new entrants

Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034

Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

Strategic recommendations in key business segments based on the market estimations

Competitive landscaping mapping the key common trends

Company profiling with detailed strategies, financials, and recent developments

Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
 - 2.4.1 Data Mining
 - 2.4.2 Data Analysis
 - 2.4.3 Data Validation
 - 2.4.4 Research Approach
- 2.5 Research Sources
 - 2.5.1 Primary Research Sources
 - 2.5.2 Secondary Research Sources
 - 2.5.3 Assumptions

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Application Analysis
- 3.7 End User Analysis
- 3.8 Emerging Markets
- 3.9 Impact of Covid-19

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 GLOBAL NEUTRALIZING ANTIBODY MARKET, BY ANTIBODY TYPE

- 5.1 Introduction
- 5.2 Monoclonal Antibodies
- 5.3 Polyclonal Antibodies
- 5.4 Broadly Neutralizing Antibody
- 5.5 Cross Neutralizing Antibody
- 5.6 Other Antibody Types

6 GLOBAL NEUTRALIZING ANTIBODY MARKET, BY TARGET VIRUS

- 6.1 Introduction
- 6.2 SARS-CoV-2
- 6.3 Influenza
- 6.4 HIV
- 6.5 Ebola
- 6.6 Hepatitis C
- 6.7 Zika
- 6.8 Other Target Viruses

7 GLOBAL NEUTRALIZING ANTIBODY MARKET, BY DISTRIBUTION CHANNEL

- 7.1 Introduction
- 7.2 Distributors
- 7.3 Online Retail

8 GLOBAL NEUTRALIZING ANTIBODY MARKET, BY APPLICATION

- 8.1 Introduction
- 8.2 Diagnostics
- 8.3 Therapeutics
- 8.4 Research & Development
- 8.5 Other Applications

9 GLOBAL NEUTRALIZING ANTIBODY MARKET, BY END USER

- 9.1 Introduction
- 9.2 Hospitals
- 9.3 Pharmaceutical Companies

9.4 Laboratories

9.5 Other End Users

10 GLOBAL NEUTRALIZING ANTIBODY MARKET, BY GEOGRAPHY

10.1 Introduction

10.2 North America

10.2.1 US

10.2.2 Canada

10.2.3 Mexico

10.3 Europe

10.3.1 Germany

10.3.2 UK

10.3.3 Italy

10.3.4 France

10.3.5 Spain

10.3.6 Rest of Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 New Zealand

10.4.6 South Korea

10.4.7 Rest of Asia Pacific

10.5 South America

10.5.1 Argentina

10.5.2 Brazil

10.5.3 Chile

10.5.4 Rest of South America

10.6 Middle East & Africa

10.6.1 Saudi Arabia

10.6.2 UAE

10.6.3 Qatar

10.6.4 South Africa

10.6.5 Rest of Middle East & Africa

11 KEY DEVELOPMENTS

- 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 11.2 Acquisitions & Mergers
- 11.3 New Product Launch
- 11.4 Expansions
- 11.5 Other Key Strategies

12 COMPANY PROFILING

- 12.1 GlaxoSmithKline plc
- 12.2 Novartis AG
- 12.3 Regeneron Pharmaceuticals, Inc.
- 12.4 Roche Holding AG
- 12.5 Eli Lilly and Company
- 12.6 Sanofi SA
- 12.7 AstraZeneca PLC
- 12.8 Merck & Co.Inc.
- 12.9 Pfizer Inc.
- 12.10 Takeda Pharmaceutical Company Limited
- 12.11 Moderna, Inc.
- 12.12 Johnson & Johnson
- 12.13 BioNTech SE
- 12.14 CSL Limite
- 12.15 Sinovac Biotech Ltd
- 12.16 HaemaLogiX Ltd

List Of Tables

LIST OF TABLES

Table 1 Global Neutralizing Antibody Market Outlook, By Region (2023–2034) (\$MN)

Table 2 Global Neutralizing Antibody Market Outlook, By Antibody Type (2023–2034) (\$MN)

Table 3 Global Neutralizing Antibody Market Outlook, By Monoclonal Antibodies (2023–2034) (\$MN)

Table 4 Global Neutralizing Antibody Market Outlook, By Polyclonal Antibodies (2023–2034) (\$MN)

Table 5 Global Neutralizing Antibody Market Outlook, By Broadly Neutralizing Antibody (2023–2034) (\$MN)

Table 6 Global Neutralizing Antibody Market Outlook, By Cross Neutralizing Antibody (2023–2034) (\$MN)

Table 7 Global Neutralizing Antibody Market Outlook, By Other Antibody Types (2023–2034) (\$MN)

Table 8 Global Neutralizing Antibody Market Outlook, By Target Virus (2023–2034) (\$MN)

Table 9 Global Neutralizing Antibody Market Outlook, By SARS-CoV-2 (2023–2034) (\$MN)

Table 10 Global Neutralizing Antibody Market Outlook, By Influenza (2023–2034) (\$MN)

Table 11 Global Neutralizing Antibody Market Outlook, By HIV (2023–2034) (\$MN)

Table 12 Global Neutralizing Antibody Market Outlook, By Ebola (2023–2034) (\$MN)

Table 13 Global Neutralizing Antibody Market Outlook, By Hepatitis C (2023–2034) (\$MN)

Table 14 Global Neutralizing Antibody Market Outlook, By Zika (2023–2034) (\$MN)

Table 15 Global Neutralizing Antibody Market Outlook, By Other Target Viruses (2023–2034) (\$MN)

Table 16 Global Neutralizing Antibody Market Outlook, By Distribution Channel (2023–2034) (\$MN)

Table 17 Global Neutralizing Antibody Market Outlook, By Distributors (2023–2034) (\$MN)

Table 18 Global Neutralizing Antibody Market Outlook, By Online Retail (2023–2034) (\$MN)

Table 19 Global Neutralizing Antibody Market Outlook, By Application (2023–2034) (\$MN)

Table 20 Global Neutralizing Antibody Market Outlook, By Diagnostics (2023–2034) (\$MN)

Table 21 Global Neutralizing Antibody Market Outlook, By Therapeutics (2023–2034) (\$MN)

Table 22 Global Neutralizing Antibody Market Outlook, By Research & Development (2023–2034) (\$MN)

Table 23 Global Neutralizing Antibody Market Outlook, By Other Applications (2023–2034) (\$MN)

Table 24 Global Neutralizing Antibody Market Outlook, By End User (2023–2034) (\$MN)

Table 25 Global Neutralizing Antibody Market Outlook, By Hospitals (2023–2034) (\$MN)

Table 26 Global Neutralizing Antibody Market Outlook, By Pharmaceutical Companies (2023–2034) (\$MN)

Table 27 Global Neutralizing Antibody Market Outlook, By Laboratories (2023–2034) (\$MN)

Table 28 Global Neutralizing Antibody Market Outlook, By Other End Users (2023–2034) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

I would like to order

Product name: Neutralizing Antibody Market Forecasts to 2034 – Global Analysis By Antibody Type (Monoclonal Antibodies, Polyclonal Antibodies, Broadly Neutralizing Antibody, Cross Neutralizing Antibody and Other Antibody Types), Distribution Channel, Application, End User and By Geography

Product link: <https://marketpublishers.com/r/NCB4CDDC9BCBEN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NCB4CDDC9BCBEN.html>